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The rapid spread of triclabendazole resistance in veterinary medicine is an important 26 
motivation for fasciocidal drug discovery and development. The aim of this study was to 27 
characterize the fasciocidal properties of 1,2,4,5-tetraoxane (MT04 and MT14) and 28 
1,2,4-trioxane (ST16 and ST28) analogues of the fasciocidal drug candidate OZ78, an 29 
1,2,4-trioxolane. Dose response relationships were determined against juvenile and 30 
adult Fasciola hepatica in rats and Echinostoma caproni in mice. The temporal effects of 31 
MT04, MT14, ST16, and ST28 compared to OZ78 on the viability of F. hepatica were 32 
tested in vitro. The heat flow of OZ78 and MT04 treated flukes was studied with 33 
isothermal microcalorimetry. Finally, surface changes to adult flukes were monitored by 34 
scanning electron microscopy (SEM) 18, 24, and 48 h post-treatment of rats with 50 35 
mg/kg MT04. Administration of 50-100 mg/kg of the synthetic peroxides resulted in 36 
complete elimination of adult F. hepatica from rats. SEM pictures revealed sloughing and 37 
blebbing already 18 h post-treatment with MT04. MT04 (100 mg/kg) cured infections with 38 
juvenile F. hepatica, whereas MT14, ST16, and ST28 showed only low to moderate 39 
worm burden reductions. At 300 mg/kg, MT14 was the only compound to completely 40 
eliminate worms from E. caproni infected mice. MT14 showed the highest activity against 41 
juvenile F. hepatica in vitro. MT04 was very active against adult F. hepatica in vitro, 42 
which was confirmed by heat flow measurements. In conclusion, we have identified 43 
MT04 as another lead compound with potential against F. hepatica, hence further 44 
preclinical studies are necessary to determine if MT04 can be considered a drug 45 
development candidate. 46 
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1. Introduction 52 
Fasciola hepatica and F. gigantica are hepatic plant-borne trematodes causing 53 
fascioliasis (Keiser and Utzinger, 2009; Robinson and Dalton, 2009). Fascioliasis is an 54 
important public health problem in many countries on different continents (Bolivia, Chile, 55 
Cuba, Ecuador, Egypt, France, Peru, Portugal and Spain) (Mas-Coma et al., 2007). It 56 
has been estimated that more than 91 million people are at risk of infection, with 2.4-17 57 
million infections (Keiser and Utzinger, 2009). In the veterinary field, the economic loss 58 
due to fascioliasis of cattle and sheep is enormous (Schweizer et al., 2005).  59 
Today’s first line therapy of infections with Fasciola spp. is triclabendazole 60 
(Fasinex®, Egaten®), a benzimidazole anthelminthic, which is highly effective against 61 
immature and mature flukes. The drug is widely available in veterinary medicine but 62 
registered in only four countries for the treatment of human fascioliasis (Fairweather, 63 
2009; Fairweather and Boray, 1999). Triclabendazole-resistant F. hepatica populations, 64 
which have emerged on different continents in sheep and cattle, are of major concern 65 
such as Australia and North Europe (Moll et al., 2000), but poorly studied and 66 
documented in some parts of the world, such as the Andean Region, where 67 
triclabendazole is widely used in cattle (Espinoza et al., 2010).   68 
The rapid spread of triclabendazole resistance is an important motivation for 69 
fasciocidal drug discovery. Recent studies have shown that the artemisinins and the 70 
synthetic 1,2,4-trioxolane (ozonide) OZ78 have potent flukicidal activity (Halferty et al., 71 
2009; Keiser et al., 2006; Vennerstrom et al., 2004). In an effort to identify more effective 72 
trematocidal synthetic peroxides, a structurally diverse library of OZ78 analogues was 73 
recently studied. It was found that a peroxide group, a spiroadamantane substructure 74 
and acidic functional group (or ester prodrug) were required for fasciocidal activity (Zhao 75 
et al., 2010). We also observed that 1,2,4-trioxane and 1,2,4,5-tetraoxane isosteres are 76 
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usually more effective than the corresponding 1,2,4-trioxolanes (unpublished 77 
observation).  78 
The aim of the present work was to study and compare the fasciocidal activity of 79 
synthetic peroxides MT04, MT14, ST16, and ST28 (Figure 1). We determined dose-80 
response relationships against juvenile and adult F. hepatica in vitro and in vivo. We 81 
studied the in vivo effect of the compounds against the intestinal fluke Echinostoma 82 
caproni, a non-haematophagous feeder to determine the contribution of haemoglobin 83 
digestion to the activity of these peroxides. Finally, scanning electron microscopy (SEM) 84 
and isothermal microcalorimetry was used to characterize the fasciocidal properties of 85 
MT04 in greater detail.  86 
 87 
2. Materials and methods 88 
2.1. Ethical clearance, parasites and host-parasite model  89 
All animal studies were carried out at the Swiss Tropical and Public Health Institute 90 
(Basel, Switzerland) and were approved by Swiss and cantonal authorities (permission: 91 
2070). Female Wistar rats (n=124, age: 4-5 weeks, weight: ~ 150 g) and female NMRI 92 
mice (n=36, age: 3-4 weeks, weight: ~ 20 g) were purchased from RCC (Horst, The 93 
Netherlands). Animals were kept in groups of 5 (rats) and 10 (mice) in macrolon cages in 94 
environmentally-controlled conditions (temperature: ~ 25°C; humidity: ~ 70%; 12 h 95 
light/dark cycle) and acclimatized for one week. They had free contact to water and 96 
rodent diet.  97 
Metacercariae (Pacific Northwest Wild Strain) of F. hepatica were purchased from 98 
Baldwin Aquatics (Monmouth, OR, USA). Metacercarial cysts of E. caproni were 99 
obtained from infected Biomphalaria glabrata snails kept in our laboratories.  100 
 101 
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2.2. Test compounds 102 
OZ78, MT04, MT14, ST16, and ST28 were synthesized following literature 103 
methods (Tang et al., 2005). The chemical structures of MT04, MT14, ST16, ST28, and 104 
OZ78 are depicted in Figure 1.  105 
<Figure 1 near here> 106 
For the in vivo studies MT04, MT14, ST16, and ST28 were suspended in 7% (v/v) 107 
Tween-80 and 3% (v/v) ethanol. Stock solutions of MT04, MT14, ST16, ST28, and OZ78 108 
were prepared in 60% in DMSO (v/v) for in vitro studies.  109 
 110 
2.3. In vivo studies  111 
2.3.1. Fasciola hepatica infection 112 
Approximately 20 metacercarial cysts of F. hepatica were orally administered to 113 
each rat using the gavage technique. Three (juvenile infection) and eight (adult infection) 114 
weeks post-infection, groups of 3 to 4 rats were treated orally with MT04, MT14, ST16, 115 
and ST28 at single doses of 25-100 mg/kg. Untreated rats served as controls. One week 116 
after treatment, rats were killed using CO2. The livers of rats harbouring juvenile flukes 117 
were flattened and examined for the presence of worms. Adult F. hepatica flukes were 118 
harvested from the livers and excised bile ducts and placed in Petri dishes. The worm 119 
count and the viabilities of all flukes recovered were recorded.  120 
 121 
2.3.2. Echinostoma caproni infection 122 
Approximately 35 metacercarial cysts of E. caproni were applied to each mouse 123 
using the gavage technique. Two weeks post-infection, 5 groups of 3 to 5 mice were 124 
treated orally with MT04, MT14, ST16, and ST28 at single 150-300 mg/kg oral doses. 125 
Untreated mice served as control. Seven days after treatment, mice were euthanized by 126 
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CO2. At necropsy, all E. caproni were removed from the pylorus to the ilecaecal valve of 127 
the mice and counted.  128 
 129 
2.4. SEM observations 130 
Three rats were infected orally with 20 F. hepatica metacercariae each. Eight 131 
weeks post-infection, the rats were treated with MT04 (50 mg/kg). At 18, 24, and 48 h 132 
post-treatment, respectively one rat was killed by CO2. Flukes were collected from the 133 
livers and bile ducts and fixed for 24 h in 2.5% glutaraldehyde in PBS buffer at room 134 
temperature. The specimens were then thoroughly washed with buffer, dehydrated with 135 
ethanol and critically point dried (Bomar SPC-900; Tacoma, USA). Flukes were mounted 136 
on aluminum stubs, sputter-coated with gold of 20 nm (Baltec Med 020, Tucson, USA) 137 
and observed in a high-resolution SEM (Philips XL30 ESEM; Eindhofen, the 138 
Netherlands) at an accelerating voltage of 5 kV.  139 
 140 
2.5. In vitro studies 141 
Adult and juvenile F. hepatica flukes were recovered from livers and bile ducts of 142 
infected rats. In addition, adult F. hepatica collected from infected bovine livers obtained 143 
from the local slaughterhouse (Basel, Switzerland) were used. The worms were quickly 144 
washed with 0.9% (w/v) NaCl and placed in 6 or 12-well plates (Costar).  145 
Culture medium in each well contained RPMI 1640 (Gibco) at 37°C, which was 146 
supplemented with antibiotics (50 µg/ml streptomycin and 50 IU/ml penicillin; Gibco) and 147 
80 µg/ml of a haemin solution. The haemin solution was prepared as follows: 5 mg 148 
haemin was dissolved in 1 ml of 0.1 M aqueous solution of NaOH, and 3.95 ml of PBS 149 
(pH = 7.4) and 0.05 ml of 1 M HCl were added to adjust the pH to 7.1 – 7.4 (Keiser and 150 
Morson, 2008). Cultures were kept at 37°C in an atmosphere of 5% CO2. 151 
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To monitor the temporal drug effect of MT04, MT14, ST16, ST28, and OZ78 in 152 
vitro, 3-6 flukes were incubated for 72 h in the presence of 50 µg/ml of the test drugs. At 153 
24, 48, and 72 h, worms were examined using a dissecting microscope. For the adult 154 
worms, a viability scale ranging from 4 (normal movements) to 1 (death; no movement 155 
observed for two min using a microscope) was used. The experiment was repeated 2-4 156 
times. For the juvenile worms, we applied a viability scale from 3 (normal movements 157 
observed using a microscope) to 1 (death; no movement observed for two min using a 158 
microscope). 159 
 160 
2.6. Microcalorimetry 161 
 A multi-channel isothermal multi-calorimeter (Model “TAM III”, TA instruments, 162 
New Castle, DE) was used to monitor the heat-production of F. hepatica over time as a 163 
result of their metabolic activity. The calorimeter was set at 37°C two days before the 164 
start of the experiment. All materials used were sterilized and drug solutions were sterile 165 
filtered (0.2 µm). 166 
Worms recovered from the bile ducts of infected rats were washed and placed in 167 
20 ml glass ampoules containing 3 ml culture medium supplemented with antibiotics, 168 
haemin-solution, and drug solution as described above. The heat-flow of 4 flukes 169 
(incubated in 50 µg/ml OZ78), 5 flukes (incubated in 50 µg/ml MT04) and 5 controls was 170 
recorded every 10 min over 96 h. Drug effects were analysed by comparing the heat-171 
flow curves of medium containing dead worms or medium only, worms alive with no 172 
treatment, and worms incubated in drug solution. Inhibition of activity of adult F. hepatica 173 
was calculated by comparing (random) oscillation amplitudes, which were derived from 174 
the worm motor activities (Fig. 2) of untreated and treated worms (Manneck et al., 2011). 175 
<Figure 2 near here> 176 
2.7. Statistical analysis  177 
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Statistical analyses were performed with version 2.4.5 of StatsDirect statistical 178 
software (StatsDirect Ltd; Cheshire, UK). Average worm burdens were expressed as 179 
arithmetic means. The Kruskal-Wallis (KW) test was applied to compare the medians of 180 
the responses between the treatment and control groups. A difference in median was 181 
considered to be significant at a level of 5%. Analyses of noise amplitudes for 182 
calorimetric measurements were performed using R software  and Microsoft Excel® (R 183 
Development Core Team, 2008). 184 
 185 
3. Results 186 
3.1. Effect of MT04, MT14, ST16, and ST28 against adult and juvenile F. hepatica 187 
harboured in rats 188 
OZ78 analogues MT04, MT14, ST16, and ST28 were first administered as single 189 
100 mg/kg oral doses to rats infected with adult F. hepatica. This dose was chosen 190 
based on previous findings documented for OZ78 (ED50 of 23 mg/kg and ED99 of 99 191 
mg/kg) (Duthaler et al., 2010). In a next step, doses were titrated down to 50 and 25 192 
mg/kg. Compound efficacies from these experiments are summarized in Table 1. At 100 193 
mg/kg, all compounds were completely curative. At 50 mg/kg, MT04, ST16, and ST28 194 
resulted in worm burden reductions of 100%, respectively, whereas MT14 produced only 195 
a 61% worm burden reduction. At the lowest dose administered (25 mg/kg), MT04, 196 
ST16, and ST28 effected worm burden reductions of 71, 88, and 0%, respectively.  197 
 198 
<Table 1 near here> 199 
Since a fasciocidal drug development candidate should have a broad spectrum of 200 
activity, activities against juvenile F. hepatica were studied. Compound efficacies of 201 
MT04, MT14, ST16, and ST28 administered at 50 and 100 mg/kg oral doses to rats 202 
infected with juvenile F. hepatica are presented in Table 2. Administration of 100 and 50 203 
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mg/kg MT04 resulted in worm burden reductions of 100 and 61%, respectively, an 204 
outcome almost identical to that previously observed for OZ78, which at the same doses, 205 
decreased worm burden by 100 and 67% (Keiser et al., 2006). A significant difference 206 
was observed between MT04 treated and untreated rats in the juvenile infection model 207 
(KW = 13.26; P = 0.0003). On the other hand, low to moderate worm burden reductions 208 
(0-46%) were observed for ST16, ST28, and MT14. 209 
<Table 2 near here> 210 
 211 
3.2. Effect of OZ78 analogues against E. caproni  212 
We assessed the efficacies of the 4 OZ78 derivatives against the non-blood 213 
feeder E. caproni to obtain further insight into the mechanism of action of these 214 
compounds. In more detail, our goal was to determine whether trematocidal activity 215 
entirely depends on haeme iron-mediated reactivity or whether also other targets are 216 
involved. In addition, as juvenile F. hepatica show a preference for hepatic cells rather 217 
than blood (Dawes, 1961) we were wondering whether there would be a relationship 218 
between an echinostomicidal activity and activity against juvenile F. hepatica. At 300 219 
mg/kg, MT04, ST16, and ST28 showed no activity against E. caproni in mice. In 220 
comparison, 1000 mg/kg OZ78 was required for good echinostomicidal activity (Keiser et 221 
al., 2006). On the other hand, a worm burden reduction of 100% was observed with 222 
MT14 at 300 mg/kg (Table 3).  223 
<Table 3 near here> 224 
 225 
3.3. In vitro activity against juvenile and adult F. hepatica 226 
The temporal effects of MT04, MT14, ST16, ST28, and OZ78 (50 µg/ml) on adult 227 
F. hepatica in vitro collected from rats and bovine are presented in Figure 3A and 3B. 228 
Control Fasciola showed normal movements at all examination time points. Flukes 229 
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obtained from rats incubated in the presence of MT04 showed reduced activities at the 230 
24 h time point (mean viability: 2.3). Twenty-four h later, only minimal viability was 231 
observed (mean viability: 1.6). 72 h post-incubation with MT04, all flukes were dead. 232 
Bovine flukes incubated with 50 µg/ml MT04 showed reduced viabilities 72 h post-233 
incubation (mean viability: 1.6). Flukes incubated with ST28, and OZ78 showed reduced 234 
movements 72 h post exposure (mean viabilities rat flukes: 2.1 and 2.0 and mean 235 
viabilities bovine flukes: 1.9 and 1.8). Slightly contradictory results were observed with 236 
ST16: while flukes obtained from rats were affected by the drug 72 h post-incubation 237 
(mean viability: 1.3) a less pronounced effect on Fasciola obtained from bovines was 238 
observed at this examination time point (mean viability: 2.1). Finally, the majority of 239 
worms incubated with MT14 had died 72 h post-exposure (mean viability: 1.2; rat flukes 240 
and mean viability: 1.1 bovine flukes).  241 
<Figure 3A and 3B near here> 242 
The fasciocidal activities of the test drugs against juvenile F. hepatica in vitro are 243 
presented in Figure 3C. Control flukes were alive for 72 h. Incubation with MT14 (50 244 
µg/ml) resulted in death of all F. hepatica 48 h post-incubation. MT04, ST16, and OZ78 245 
showed no effect against juvenile flukes in vitro (mean viability after 72 h: 2.7, 2.8 and 246 
2.4, respectively). F. hepatica incubated in ST28 showed reduced movements after 72 h 247 
(mean viability: 1.5).  248 
<Figure 3C near here> 249 
 250 
3.4. Microcalorimetry of adult F. hepatica 251 
Thermogenic noise value curves of control adult F. hepatica and worms 252 
incubated with 50 µg/ml MT04 and OZ78 are depicted in Fig. 4. Consistently low signals 253 
of 1.46 µW were measured for dead worms or medium only (data not shown). The 254 
intersection of the sample amplitude curve (following exponential decay) with the 255 
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background signal noise of dead worms (1.46 µW) was set as an endpoint of worm 256 
motility. Worms incubated with MT04 and OZ78 were dead after 29.6 h and 43.4 h, 257 
respectively. Control worms were viable for 69.3 h.  258 
<Figure 4 near here> 259 
 260 
3.5. In vivo SEM observations  261 
SEM studies were only performed with MT04 since it was the most efficacious 262 
analogue of OZ78. At 18 h post-treatment with 50 mg/kg of MT04, 6 flukes were 263 
collected from a rat and processed for SEM. Disruption of the tegument was visible, in 264 
particular on the anterior region of F. hepatica where blebbing and sloughing were 265 
observed (Figures 5A and B). Twenty-four h post-treatment, we collected 2 dead 266 
specimens and 1 F. hepatica that showed minor activity. Similar abnormalities such as 267 
blebbing and furrowing, which had not progressed further in severity, were observed on 268 
these worms (Figure 5C and 5D). Forty-eight h post-treatment only dead F. hepatica 269 
were recovered and since flukes were broken they were not processed for SEM 270 
analyses.   271 
<Figure 5 near here> 272 
 273 
4. Discussion 274 
Triclabendazole is an ideal fasciocidal drug as it is orally active against both 275 
juvenile and adult F. hepatica (Fairweather and Boray, 1999). However, since drug 276 
resistance is spreading it is imperative that novel fasciocidal drugs are discovered and 277 
developed. The synthetic ozonides seem to offer an excellent starting point as recent 278 
studies showed that OZ78 is active against adult and juvenile F. hepatica in vitro and in 279 
vivo, including resistant isolates (Keiser and Utzinger, 2007). In the present work, the 280 
fasciocidal activities of 4 OZ78 analogues were studied in greater detail.  281 
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MT04 had the highest activities against both juvenile and adult F. hepatica in vivo. 282 
MT04 was superior to OZ78, in particular against adult F. hepatica. A single 50 mg/kg 283 
oral dose of MT04 achieved complete worm burden reductions against adult F. hepatica 284 
in rats, while 100 mg/kg doses of OZ78 were required to cure F. hepatica infected rats 285 
(Keiser et al., 2006). Forty-eight h after treatment with 50 mg/kg MT04, only dead flukes 286 
were recovered from a rat. Flukes collected at earlier time points showed disrupted 287 
teguments including sloughing and blebbing and some flukes had already died. 288 
Comparable tegumental alterations (blebs, sloughing, and furrows) were also seen 24-289 
72 h after treatment with 100 mg/kg OZ78 (Keiser and Morson, 2008). The main 290 
difference observed between the two drugs was the onset of action. Eighteen-24 h after 291 
treatment with MT04, F. hepatica showed reduced viabilities or had already died, 292 
whereas dead worms were collected from OZ78-treated rats 72 h post-treatment (Keiser 293 
and Morson, 2008). Whether differences in in vivo efficacy and the onset of action 294 
between the two compounds derive from pharmacodynamic or pharmacokinetic 295 
parameters is not clear, but it is evidently a function of their two different peroxide 296 
heterocycles. In this respect, O’Neill et al. have recently shown that the red blood cell 297 
stability of tetraoxanes is higher than that of the corresponding trioxolanes (ozonides) 298 
(O'Neill et al., 2010). The mechanism of action of the secondary ozonides against 299 
Fasciola spp. has not yet been elucidated. However, a formation of carbon-centered 300 
radicals, similar to the antimalarial mechanism of action might play a role (Dong et al., 301 
2010). 302 
Our in vitro studies on adult F. hepatica confirmed the excellent flukicidal activity of 303 
MT04. After 72 h, the majority of adult worms incubated in presence of 50 µg/ml MT04 304 
were dead. It is interesting to note that OZ78 and MT04 did not show any effects against 305 
juvenile F. hepatica in vitro in line with results obtained with OZ78 in a recent study 306 
(Duthaler et al., 2010). Why juveniles are affected in vivo, but not in vitro is not known, 307 
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but drug metabolism may account for these differences. A good relationship with regard 308 
to compound sensitivity was observed between the F. hepatica Pacific Northwest wild 309 
strain harboured in rats and bovine slaughterhouse isolates, although flukes obtained 310 
from infected bovine livers were slightly less susceptible to the test drugs. 311 
We speculated that a drug effect against E. caproni might point to an activity 312 
against juvenile F. hepatica, since both parasites do not feed on large quantities of blood 313 
(Dawes, 1961; Keiser and Utzinger, 2007). However, no relationship was observed 314 
between drug sensitivities on echinostomes and juvenile F. hepatica. Though ST16 and 315 
ST28 lacked activity against both parasite stages, MT14 had activity against E. caproni, 316 
while lacking activity against juvenile F. hepatica in vivo. On the other hand, MT04 317 
revealed no activity against echinostomes but cured infections with juvenile F. hepatica.  318 
We have shown for the first time that heat flow measurements are an excellent 319 
tool to study the effects of fasciocidal drugs. The usefulness of this method to study drug 320 
effects on helminths has recently been demonstrated for another trematode, namely 321 
Schistosoma mansoni (Manneck et al., 2011). In the present work, heat flow 322 
measurements confirmed data obtained by morphological in vitro testing.  323 
Microcalorimetry showed that worms incubated in MT04 died earlier than worms 324 
incubated with OZ78. Compared to our standard in vitro assays, untreated worms died 325 
earlier (69 hours) which might be due to a lack of oxygen in the calorimetry vials. Further 326 
studies are currently ongoing in our laboratories, including experiments with juvenile 327 
flukes and the reference drug triclabendazole in order to validate and standardize the 328 
use of microcalorimetry to study drug effects on Fasciola spp..  329 
In conclusion, this assessment of 4 promising synthetic peroxide derivatives of 330 
OZ78 has identified MT04 as another lead compound with potential against F. hepatica 331 
and perhaps other haemoglobin-degrading flukes. We anticipate that ongoing 332 
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pharmacokinetic and mechanism of action studies with MT04 should provide the 333 
necessary data to determine if MT04 can be considered a drug development candidate.  334 
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Figure legend: 433 
 434 
Figure 1: Chemical structures of MT04, MT14, ST16, ST28, and OZ78. 435 
Figure 2: Noise analysis of adult F. hepatica (A): heat-flow curve of a sample containing 436 
1 adult worm, showing the occurrence of noise/oscillations over time (black curve). 437 
Oscillations amplitude values follow exponential decay (grey curve) (B): magnification of 438 
oscillations derived from A, (C): Maximum values of the amplitude over a window of 20 439 
min during the entire course of the experiment. The intersection of the background noise 440 
of the calorimetric system (grey dotted line) with the smoothed sample curve (grey 441 
curve) is the endpoint and corresponds to the calculated death of the worm. 442 
Figure 3A: In vitro activity of MT04, MT14, ST16, and ST28 at a concentration of 50 443 
µg/ml against adult F. hepatica (obtained from rats) compared to control worms and 444 
worms incubated with OZ78 (50 µg/ml). Black line with white diamond: control; black 445 
dotted line with black circle: OZ78; black line with black square: MT04; grey line with 446 
white circle: MT14; dotted and dashed black line with black diamond: ST16; grey line 447 
with black triangle: ST28. The limits of the whiskers correspond to the standard error of 448 
the mean values per time point. 449 
Figure 3B: In vitro activity of MT04, MT14, ST16, and ST28 at a concentration of 50 450 
µg/ml against adult F. hepatica (obtained from bovine livers) compared to control worms. 451 
Black line with white diamond: control; black dotted line with black circle: OZ78; black 452 
line with black square: MT04; grey line with white circle: MT14; dotted and dashed black 453 
line with black diamond: ST16; grey line with black triangle: ST28. The limits of the 454 
whiskers correspond to the standard error of the mean values per time point. 455 
Figure 3C: In vitro activity of 50 µg/ml MT04, MT14, ST16, and ST28 against juvenile F. 456 
hepatica compared to control worms and worms incubated with OZ78 50 µg/ml. Black 457 
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line with white diamond: control; black dotted line with black circle: OZ78; black line with 458 
black square: MT04; grey line with white circle: MT14; dotted and dashed black line with 459 
black diamond: ST16; grey line with black triangle: ST28. The limits of the whiskers 460 
correspond to the standard error of the mean values per time point. 461 
Figure 4: Absolute noise values of untreated and treated worms (OZ78 50 µg/ml and 462 
MT04 50 µg/ml). Dotted black line: background; black line: MT04, dark-grey shaded line: 463 
OZ78, light-grey line: control. 464 
Figure 5A-D: Fig. 5A, B: SEM observation of adult F. hepatica 18 h post treatment with 465 
50 mg/kg MT04. (A) Disruption and sloughing (s) of the tegument near the oral sucker 466 
(OS). (B) Blebbing (b) observed on the tegument. Fig. 5C, D: SEM observation of adult 467 
F. hepatica 24 h post treatment with 50 mg/kg MT04. (C) Blebs in the OS region, (D) 468 
furrows (f) visible in the mid body region.  469 
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 Table 1: Worm burden reductions achieved against adult F. hepatica harboured in rats following the administration of 
MT04, MT14, ST16, and ST28 at different doses.  
Treatment Dose 
(mg/kg) 
No. of rats 
investigated 
No. of rats 
cured 
Mean worm 
burden  
Total flukes 
recovered 
Total worm 
burden 
reduction (%) 
KW P 
Live Dead    
Control -
1
 7 0 7.7 54 0 -   
-
2
 7 0 7 49 0 -   
-
3
 5 0 2 10 0 -   
-
4
 5 0 7.2 36 0 -   
-
5
 5 0 4 20 0 -   
-
6
 7 0 7.6 53 0 -   
MT04 25
1
 4 0 2.25 9 0 70.8 
17.06 <0.0001 50
4
 4 4 0 0 3 100 
100
4
 4 4 0 0 7 100 
MT14 50
2
 4 1 2.75 11 3 60.7 
11.96 0.0005 
100
6
 3 3 0 0 8 100 
ST16 25
3
 4 3 0.25 1 0 87.5 
17.48 <0.0001 50
2
 4 4 0 0 1 100 
100
2
 3 3 0 0 1 100 
ST28 25
5
 4 1 5 20 0 0 
2.625 0.1052 50
5
 3 3 0 0 7 100 
100
5
 3 3 0 0 0 100 
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KW Kruskal Wallis; Superscript number matches control group with the corresponding treatment group 
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Table 2: Worm burden reductions achieved against juvenile F. hepatica harboured in rats following the administration of MT04, MT14, 
ST16, and ST28 at two different doses.  
KW Kruskal Wallis  
Superscript number matches control group with the corresponding treatment group 
 
Treatment  Dose (mg/kg) No. of rats  
investigated 
No. of rats  
cured 
Mean worm 
 burden  
Total flukes 
recovered  
Total worm 
burden reduction 
(%) 
KW P 
Live  Dead    
Control  -
1
 7 0 7 49 0 -   
-
2
 4 0 6.75 27 0 -   
-
3
 3 0 8.33 25 0 -   
MT04 50
1
 4 0 2.75 11 0 60.7 
13.26 0.0003 
100
2
 6 6 0 0 2 100 
MT14 50
3
 4 0 7.75 31 0 7.0 
0.52 0.4688 
100
3
 4 0 6.75 27 0 19.0 
ST16 50
2
 4 0 5.75 23 0 14.8 
1.44 0.2304 
100
2
 4 0 3.75 15 0 44.4 
ST28 50
3
 4 0 10.5 42 0 0 
0.17 0.6789 
100
3
 4 0 4.5 18 0 46.0 
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Table 3: Worm burden reductions achieved against adult E. caproni harboured in mice following the administration of MT04, MT14, 
ST16, and ST28 at different doses. 
 
KW Kruskal Wallis  
Superscript number matches control group with the corresponding treatment group 
 
 
Treatment  Dose 
(mg/kg) 
No. of mice  
investigated 
No. of mice  
Cured 
Mean worm 
 burden  
Total flukes 
recovered  
Total worm 
burden 
reduction (%) 
KW P 
Live  Dead    
Control  -
1
 7 0 19.9 139 0 -   
-
2
 5 0 24.2 121 0 -   
-
3
 5 0 29.6 148 0 -   
MT04 300
3
 4 1 13.5 54 0 54.4 5.46 0.0195 
MT14 150
2
 5 1 15 75 0 38.0 
5.59 0.0180 
300
1
 3 3 0 0 0 100 
ST16 300
2
 3 0 25.7 77 0 0 0.02 0.8815 
ST28 300
2
 4 0 20 80 0 17.4 1.54 0.2148 
